GWPH up +5.56% percent Today $GWPH High is at 80.6

GWPH up +5.56% percent Today $GWPH High is at 80.66 and the Low 77.00 with current volume of 168,722.

Recent News posted below.

Gw Pharmaceuticals Plc Ads GWPH other info.
http://investorshangout.com/GW-Pharmaceuticals-GWPH-62459/

GWPH Gw Pharmaceuticals Plc Ads Recent Headline News

Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 7 mins ago
Enzymotec Ltd. (ENZY) was a big mover last session, as the company saw its shares surge 15% on the day.
ICUI: 86.48 (+0.78), ABAX: 54.91 (+0.25), GWPH: 79.74 (+3.18), ENZY: 8.30 (-0.06)

Allscripts, MaineGeneral Health Extend EHR Alliance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 12:40PM CST
With the multi-year extension, MaineGeneral intends to leverage new and innovative EHR solutions from Allscripts Healthcare Solutions, Inc. (MDRX) to deliver the highest value to its clinical community.
GWPH: 79.74 (+3.18), STRM: 3.88 (+0.06), MDRX: 12.30 (unch), MRGE: 3.26 (+0.07)

GW Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Mon Nov 17, 9:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group" , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference in London, England on Wednesday, 19 November, 2014 at 4:20 p.m. GMT/11:20 a.m. EST time.
GWPH: 79.74 (+3.18)

Weakness Seen in Vascular Solutions (VASC): Stock Plunges 22.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:52AM CST
Vascular Solutions has been witnessing a negative trend in its current year earnings estimate and its share price has showed a sharp decline in the last 24 hours
ICUI: 86.48 (+0.78), INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18), VASC: 25.01 (+0.53)

Why We Don't Buy Marijuana Stocks
Motley Fool Staff - Motley Fool - Mon Nov 17, 7:33AM CST
Source: GW Pharmaceuticals Medical marijuana is one of healthcare's biggest stories this year and shares in marijuana companies are trading near all time highs, but not everyone is convinced that marijuana stocks should be in investor portfolios....
INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18)

Forget Marijuana! This Is a Much Smarter Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 16, 11:11AM CST
Source: Flickr user Oswaldo. Although marijuana initiatives didn't log a perfect sweep in this year's midterm elections, the momentum behind the legalization movement remains intact. Two states (Oregon and Alaska), as well as Washington, D.C.,...
JNJ: 108.98 (+0.68), INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18), GSK: 46.18 (+0.30), NVS: 95.41 (+1.03)

3 Reasons You Can Buy This Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 15, 5:15PM CST
Source: GW Pharmaceuticals Marijuana stocks have surged this year on enthusiasm over their potential use as medicine for the treatment of a range of disease that stretches from epilepsy to diabetes. But just because many medical marijuana stocks...
INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18)

This Could Be the Make-or-Break Marijuana State
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 15, 11:09AM CST
Source: Flickr user Poporin.  It's been a largely positive, but still topsy-turvy, year for both legal marijuana and medical marijuana in 2014. Following landmark victories in 2012 that legalized recreational, adult-use marijuana in...
INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18)

Will GW Pharmaceuticals (GWPH) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 4:57PM CST
GW Pharmaceuticals plc (GWPH) is expected to report fourth-quarter fiscal 2014 results on Nov 18.
MNK: 88.50 (+0.07), IPXL: 29.25 (+0.54), INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18)

Strength Seen in Cerus (CERS): Stock Gains 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 8:25AM CST
Cerus (CERS) was a big mover last session, with shares rising nearly 6% on the day.
CERS: 4.25 (-0.03), ABAX: 54.91 (+0.25), GWPH: 79.74 (+3.18), OSUR: 8.92 (+0.11)

Why GW Pharmaceuticals (GWPH) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:46AM CST
GW Pharmaceuticals has decent short-term momentum and is also seeing solid activity on the earnings estimate revision front for the coming quarter and year.
GWPH: 79.74 (+3.18)

Allscripts Healthcare and CHI Sign Hosting Solution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:40PM CST
By utilizing Allscripts Healthcare Solutions, Inc. (MDRX) Hosting Solution, Catholic Health Initiatives expects improved system availability, reduced IT infrastructure expenditures as well as enhanced end user performance.
GWPH: 79.74 (+3.18), ABAX: 54.91 (+0.25), MDRX: 12.30 (unch), MRGE: 3.26 (+0.07)

INSYS Therapeutics (INSY) in Focus: Stock Rises 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:44AM CST
INSYS Therapeutics, Inc. (INSY) was a big mover last session, as the company saw its shares surge 12%
ICUI: 86.48 (+0.78), INSY: 38.88 (+0.99), ABAX: 54.91 (+0.25), GWPH: 79.74 (+3.18)

Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 54.91 (+0.25), GWPH: 79.74 (+3.18), OSUR: 8.92 (+0.11), OMER: 20.77 (+1.03)

Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 38.88 (+0.99), GWPH: 79.74 (+3.18), TEVA: 57.45 (+0.21), GSK: 46.18 (+0.30)

CannLabs; Growing a Presence in a Burgeoning Industry
ACCESSWIRE - Tue Nov 11, 8:56AM CST
WHITEFISH, MT / ACCESSWIRE / November 11, 2014 / The U.S. cannabis industry could reach between $21 billion and $35 billion by 2020, according to Green Wave Advisors, depending on the number of states that successfully legalize the drug over the coming years. As more states implement their own programs, there is a growing need for high-quality testing services in order to ensure high-quality and safe products for both medical and recreational users.
GWPH: 79.74 (+3.18)

Eagle Pharmaceuticals (EGRX) Jumps: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:46AM CST
Eagle Pharmaceuticals (EGRX) was a big mover last session, with shares rising over 8% on the day.
ICUI: 86.48 (+0.78), ABAX: 54.91 (+0.25), GWPH: 79.74 (+3.18), EGRX: 12.45 (-0.05)

Cannabis Legalization Wins Out in Midterm Elections
ACCESSWIRE - Mon Nov 10, 10:00AM CST
WHITEFISH, MT / ACCESSWIRE / November 10, 2014 / Cannabis stocks moved lower over the past week, according to data from the MarijuanaIndex(TM), despite favorable outcomes in the mid-term elections. Industry bellwethers, like GW Pharmaceuticals plc (NASDAQ: GWPH), traded largely sideways, although MedBox Inc. (OTC: MDBX) fell more than 20%.
GWPH: 79.74 (+3.18)

Cannabix Marijuana Breathalyzer Could Help Separate Users From Impaired
ACCESSWIRE - Mon Nov 10, 8:48AM CST
WHITEFISH, MT / ACCESSWIRE / November 10, 2014 / Federal Schedule I regulations on medical marijuana (MMJ) and recreational use are changing with each passing day as states continue to hammer out their own policy frameworks, spurred on by sizeable additions to state coffers as a result of tax revenues. Pew Research Center survey data from earlier this year also shows that for the first time since 1969, when only 12% of Americans favored legalization, more than half (54%) the country is now in favor of making marijuana legal. With 23 states and D.C. now having either some form of MMJ legislation, or open recreational use on the books (as in Colorado and Washington), cash-strapped state budget makers are likely looking closely at data points like the Denver Business Journal's analysis of Colorado's recreational market, which forecasts around $70M in tax revenues this fiscal year. In Oregon, where a ballot vote for legalization is set to take place in November, the state's Legislative Revenue Office estimates 2017 tax revenues at around $16M as a result. Recent in-depth analysis by NerdWallet even put the upper limit for Oregon around $100M per annum, and with a nationwide projection of as much as $3.1B, it seems clear that the tax revenue factor could lead to more easing from the feds. On November 4th, Washington D.C. voters looked to join Colorado and Washington State in legalizing adult-use marijuana after backing Initiative 71 at the voting booths. With voters backing the bill 7-to-3, the initiative will permit anyone over the age of 21 to legally possess as much as two ounces of marijuana and to grow up to three marijuana plants at home.
GWPH: 79.74 (+3.18)

Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.21 (+0.12), ABAX: 54.91 (+0.25), GWPH: 79.74 (+3.18), OSUR: 8.92 (+0.11)